Trivalent fowl adenovirus vaccine (serotype-4/8b/11) provides efficient protection with long duration of immunity
- Author:
Dam-Hee PARK
1
;
Kyeong-Cheol MIN
;
Na-Ri KIM
;
Sung-Sik YOO
;
Injoong YOON
;
Jongseo MO
Author Information
- Publication Type:Research Report
- From:Journal of Veterinary Science 2026;27(3):e28-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:This study evaluated a novel trivalent inactivated FAdV vaccine containing antigens from FAdV-4, 8b, and 11.
Methods:An SD1356-like FAdV-8b strain, representing newly emerging variants in Asia and the Middle East, was included as an immunogen. Prior to vaccination-challenge trials, pathogenicity of FAdV-4, 8b, and 11 was assessed in chickens via oral, intramuscular, and intravenous routes. These models were used to determine the minimum protective dose.Cross-neutralization assays were performed using sera from monovalent vaccinations for each serotype. Duration of immunity was evaluated in specific pathogen-free chickens following a single vaccine dose.
Results:Intravenous challenge produced the highest mortality across all serotypes, including the relatively low-pathogenic FAdV-11. A vaccine dose of 107.0TCID50 /bird induced strong neutralizing antibody responses and provided complete protection against virulent strains.Sera showed no cross-neutralization between heterologous serotypes, emphasizing the necessity of multivalent formulations. Protective antibody titers were maintained up to 78 weeks of age.
Conclusions:and Relevance: The trivalent vaccine provides effective protection against predominant FAdV-4, 8b, and 11 strains. These findings support the use of multivalent vaccines to achieve broad and sustained immunity against emerging FAdV infections in poultry.
